Urgent need for pragmatic trial platforms in severe asthma.

[1]  J. Drazen,et al.  New Biologics for Asthma. , 2018, The New England journal of medicine.

[2]  I. Pavord,et al.  Dupilumab Efficacy and Safety in Moderate‐to‐Severe Uncontrolled Asthma , 2018, The New England journal of medicine.

[3]  J. Corren,et al.  Tezepelumab in Adults with Uncontrolled Asthma , 2017, The New England journal of medicine.

[4]  T. H. Nguyen,et al.  Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 , 2017, The Lancet. Respiratory medicine.

[5]  O. Vandenplas,et al.  Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR). , 2014, Respiratory medicine.

[6]  Ian D Pavord,et al.  Mepolizumab treatment in patients with severe eosinophilic asthma. , 2014, The New England journal of medicine.

[7]  E. Bleecker,et al.  International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma , 2013, European Respiratory Journal.

[8]  D. Postma,et al.  Integrating real-life studies in the global therapeutic research framework. , 2013, The Lancet. Respiratory medicine.

[9]  Ian D Pavord,et al.  Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial , 2012, The Lancet.

[10]  S. Wenzel.  Asthma phenotypes: the evolution from clinical to molecular approaches , 2012, Nature Medicine.

[11]  J Bousquet,et al.  Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE , 2005, Allergy.